Five major Business Development Companies (BDCs) are trading at significant discounts to their net asset value (NAV), suggesting the market expects severe loan losses that are not supported by current credit data. These BDCs hold senior secured, diversified loan portfolios with low non-accruals, and management buybacks at deep discounts indicate confidence in loan valuations. The article highlights optimism for Q3 results, expecting resilient credit quality and net interest income growth due to higher interest rates. Investors are advised to focus on BDCs with strong balance sheets and solid dividend coverage.
The story on five BDCs priced for loan losses worse than 2008 provides context for readers. For those tracking the Financials sector, 124 of 142 US stocks on Pluang rose while 18 fell as of Oct 21, 2026 02:31 WIB. Notable movers include CBOE at USD 316.85 with a 3.39% gain and a 2-day typical hold time, AVAT at USD 1.23 up 3.36%, and BX at USD 110.50 rising 3.21% with a 97-day hold time.
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
Heartland Express reported a third-quarter 2026 revenue decline of 8.7% to $179.5 million, missing analyst estimates. Despite lower revenue, the company returned to profitability with a net income of $1.0 million, compared to a loss last year. The op...
Catholic Medical Mission Board (CMMB) held a ribbon-cutting ceremony for its new Distribution Center at the Brethren Service Center in New Windsor, Maryland. This move enhances CMMB's Access to Medicines Program by expanding operational capacity and ...
Piper Sandler upgraded Myriad Genetics from Underweight to Neutral and set a $5.00 price target after the company agreed to sell its prenatal health testing business to Labcorp for $210 million in cash. This sale includes several prenatal tests and i...
Brunello Cucinelli, an Italian luxury fashion company, raised its 2026 outlook following stronger-than-expected third-quarter sales. Citigroup maintains a Buy rating on the stock, which trades around $9.43 with a market cap of approximately $6.41 bil...
